SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eli Lilly Reports 62% Response Rate for Olomorasib Combination in First-Line NSCLC

Eli Lilly reported a 62% response rate for investigational olomorasib in combination therapy for first-line KRAS G12C-mutant non-small cell lung cancer.

LLY

Related stories